HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Francisco G Medina-Rodriguez Selected Research

Biological Therapy

8/2017Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Francisco G Medina-Rodriguez Research Topics

Disease

6Rheumatoid Arthritis
12/2019 - 01/2017
1Necrosis
03/2017

Drug/Important Bio-Agent (IBA)

6Rituximab (Mabthera)FDA Link
12/2019 - 01/2017
6CT-P10IBA
12/2019 - 01/2017
5Biosimilar PharmaceuticalsIBA
12/2019 - 01/2017
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2017

Therapy/Procedure

1Biological Therapy
08/2017